



## D<sub>5</sub> dopamine receptor carboxyl tail involved in D<sub>5</sub>–D<sub>2</sub> heteromer formation

Brian F. O'Dowd<sup>a,b,\*</sup>, Tuan Nguyen<sup>a,b</sup>, Xiaodong Ji<sup>b</sup>, Susan R. George<sup>a,b,c</sup>

<sup>a</sup> Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada M5S 1A8

<sup>b</sup> Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8

<sup>c</sup> Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5S 1A8

### ARTICLE INFO

#### Article history:

Received 14 December 2012

Available online 11 January 2013

#### Keywords:

G protein coupled receptors  
D<sub>5</sub> and D<sub>2</sub> dopamine receptor  
Nuclear localization  
Protein structure  
Heteromer  
Interacting amino acids.

### ABSTRACT

We have demonstrated that D<sub>5</sub> and D<sub>2</sub> dopamine receptors exist as heteromers in cells, and determined these receptor interact through amino acids in the cytoplasmic regions of each receptor. Specifically involved in heteromer formation we identified in the carboxyl tail of the D<sub>5</sub> receptor three adjacent glutamic acid residues, and in intracellular loop 3 of the D<sub>2</sub> receptor two adjacent arginine residues. Any pairing of these three D<sub>5</sub> receptor glutamic acids were sufficient for heteromer formation. These identified residues in D<sub>5</sub> and D<sub>2</sub> receptors are oppositely charged and likely interact by electrostatic interactions.

© 2013 Elsevier Inc. All rights reserved.

## 1. Introduction

Family A G protein coupled receptors (GPCRs) form heteromers [1–3]. We have reported that dopamine D<sub>1</sub>–D<sub>2</sub> receptor heteromers exist in brain and cultured neurons [4,5]. These heteromers were subject to conformational changes and separation by agonists [6], the heteromers reformed at the cell surface when the agonist was removed [6]. Identifying specific amino acids involved in GPCR heteromer formation has been hampered by the lack of decisive methodologies. Using our process of inserting a nuclear signal (nls) into a GPCR [7] we have identified residues involved in forming heteromers. We reported that the D<sub>1</sub> and D<sub>2</sub> heteromers interact by specific residues in the cytoplasmic regions. In intracellular loop 3 (ic3) of the D<sub>2</sub> receptor, two arginine residues (274-RR) form an electrostatic interaction with vicinal glutamic residues (404-EE) in the carboxyl tail (c-tail) of the D<sub>1</sub> receptor [8]. We also recently identified cytoplasmic residues involved in mu-delta opioid heteromers [9].

Previously we demonstrated heteromerization between the D<sub>5</sub> and D<sub>2</sub> receptors, our FRET analysis showed D<sub>5</sub> and D<sub>2</sub> receptors formed a heteromeric complex [10]. The D<sub>1</sub> and D<sub>5</sub> dopamine receptors share extensive overall homology (80%), however these receptors have negligible homology in their long c-tails. We questioned if D<sub>5</sub> and D<sub>2</sub> heteromers also form by electrostatic interactions

between the D<sub>2</sub> ic3 and D<sub>5</sub> c-tail. In this report we have determined the specific amino acids in the cytoplasmic regions of D<sub>5</sub> and D<sub>2</sub> receptors involved in heteromer interactions. We demonstrated that changing the identified cytoplasmic amino acids prevented D<sub>5</sub>–D<sub>2</sub> heteromer formation.

## 2. Materials and methods

### 2.1. Fluorescent proteins

cDNA sequences encoding GFP, RFP were obtained from Clontech (Palo Alto, CA), and the receptor constructs generated as described [7].

### 2.2. Cell culture

HEK cells grown on 60 mm plates in minimum essential medium (MEM), were transfected with 0.5–2 µg cDNA using Lipofectamine (Life technologies, Rockville MD). Dopamine antagonist (+)butaclamol when used, was added to cells and cells visualized by confocal microscopy.

### 2.3. Microscopy

Live cells expressing GFP, and RFP fusion proteins were visualized with a LSM510 Zeiss confocal laser microscope. In each experiment 5–8 fields, containing 50–80 cells per field were evaluated and the entire experiment was repeated several times ( $n = 3–5$ ).

\* Corresponding author. Address: Department of Pharmacology, University of Toronto, 1 King's College Circle, Room 4353, Toronto, Ontario, Canada M5S 1A8. Fax: +1 (416) 971 2868.

E-mail address: [brian.odowd@utoronto.ca](mailto:brian.odowd@utoronto.ca) (B.F. O'Dowd).

## 2.4. DNA constructs

All the DNA encoding the GPCRs were human origin. Sequences encoding GPCRs were cloned into plasmids pEGFP, as described previously [7,11]. The D<sub>5</sub> carboxyl tail DNA PCR product, containing no stop codon was subcloned into vector RFP (BD Biosciences) at EcoR1 and Kpn1 and inframe with the start codon of RFP.

## 2.5. Receptor constructs

The D<sub>5</sub> receptor constructs were prepared using the Quick-change mutagenesis kit (Stratagene) according to the manufacturer's instructions, and as described [7,11]. Receptor DNA was subjected to PCR as previously reported [7]. The reaction mixture consisted of: H<sub>2</sub>O (32 µl), 10× Pfu buffer (Stratagene) (5 µl), dNTP (10 mM, 5 µl), DMSO (5 µl), oligonucleotide primers (100 ng, 1 µl each), DNA template (100 ng), Pfu enzyme (5 U). Total volume 50 µl. PCR conditions, one cycle at 94 °C for 2 min, 30–35 cycles at 94 °C for 30 s, 55 °C for 30 s, 72 °C for 1 min, per cycle, and then one cycle at 72 °C for 5 min. The D<sub>2</sub>-nls and D<sub>1</sub>-nls receptor construct was prepared as previously described [7].

## 3. Results

### 3.1. Identification of the D<sub>5</sub> dopamine receptor amino acids involved in D<sub>5</sub>–D<sub>2</sub> heteromer formation

The D<sub>5</sub> receptor has an extensive c-tail, extending ~93 amino acids from the palmitoylated cysteine, Fig. 1, (consists of 26% of the total D<sub>5</sub> receptor, the D<sub>1</sub> receptor c-tail is 95 amino acids in length). There is negligible homology shared between the D<sub>1</sub> and D<sub>5</sub> receptors throughout their c-tail regions.

We incorporated an NLS into the D<sub>2</sub> receptor (D<sub>2</sub>-nls), this did not alter the binding properties, with preserved agonist-detected high affinity and low affinity states, indicative of intact receptor–G protein coupling [7].

We expressed D<sub>5</sub> and D<sub>2</sub>-nls dopamine receptors in cells and demonstrated heteromer formation, Fig. 2, since the D<sub>2</sub>-nls receptor was able to translocate the D<sub>5</sub> receptor to the nucleus. Despite the lack of homology in the extensive c-tails of D<sub>1</sub> and D<sub>5</sub>, in the D<sub>5</sub> receptor c-tail there are three adjacent glutamic acids (429-EEE) in a region comparable with the glutamic acid pair (404-EE) located in the D<sub>1</sub> receptor, Fig. 1. The D<sub>1</sub> receptor glutamic acids

(404-EE) were identified as forming heteromers with the D<sub>2</sub> receptor [8]. We wished to determine if these three glutamic acids (429-EEE) located in the c-tail of the D<sub>5</sub> receptor were involved in forming heteromers with the D<sub>2</sub> receptor.


We prepared a series of six substitution constructs in the D<sub>5</sub> receptor c-tail (Table 1A), and each construct was expressed with the D<sub>2</sub>-nls receptor. These D<sub>5</sub> receptors expressed alone were located predominantly in the cytoplasm. The D<sub>5</sub> receptor c-tail constructs C1 (429-EEE to AAA), C2 (429-EEE to EAA) and C3 (429-EEE to EAE) all failed to show D<sub>5</sub>–D<sub>2</sub> heteromerization (Fig. 2 and Table 1A), since the D<sub>2</sub> receptor did not translocate these D<sub>5</sub> receptors to the nucleus. D<sub>5</sub>–D<sub>2</sub> heteromer formation was observed with D<sub>5</sub> receptor constructs C4 (429-EEE to AEE) and C5 (429-EEE to EEA), in which each contained the vicinal – EE residues. Also in C6 construct substitution of the adjacent aspartic acid (DEEE to AEEE) did not affect D<sub>5</sub>–D<sub>2</sub> heteromer formation (Fig. 2 and Table 1A). These experiments indicated a heteromer requirement of at least a pair of glutamic acids (–EE) in the D<sub>5</sub> receptor c-tail. Thus like D<sub>1</sub> receptor it appears that in the D<sub>5</sub> receptor the equivalently located glutamic acid pairs were also involved in heteromerization of D<sub>5</sub>–D<sub>2</sub> receptors. The presence of three glutamic acids (429-EEE) in the D<sub>5</sub> receptor, compared to two glutamic acids in (404-EE) in the D<sub>1</sub> receptor, would potentially allow two positions for oligomer formation with D<sub>2</sub> receptor, utilizing 429-EE or 430-EE.

### 3.2. Identification of the D<sub>2</sub> dopamine receptor amino acids involved in D<sub>5</sub>–D<sub>2</sub> receptor heteromer formation


We wished to determine if the arginines (274–RR) located in ic3 of the D<sub>2</sub> receptor were involved in forming heteromers with the D<sub>5</sub> receptor. These arginines, identified as being involved in D<sub>1</sub>–D<sub>2</sub> heteromers, were located a distance of 59 amino acids from transmembrane 5 (TM5), Fig. 1. The D<sub>2</sub>-nls receptor with these arginines substituted (274–RR to AA) and the D<sub>5</sub> receptor were co-expressed, Fig. 2. These receptors D<sub>5</sub> and D<sub>2</sub>-nls (RR to AA) did not form heteromers, confirming that both D<sub>1</sub> and D<sub>5</sub> dopamine receptors utilized the same residues in the dopamine D<sub>2</sub> receptor ic3 for heteromer formation.

### 3.3. Formation of D<sub>5</sub>–D<sub>1</sub> dopamine receptor heteromers

The D<sub>1</sub>-nls and D<sub>5</sub> receptors were co-expressed and formed heteromers, Fig. 2, since the D<sub>5</sub> receptor was visualized translocating



**Fig. 1.** Representation of the cytoplasmic intracellular tail of the D<sub>5</sub> dopamine receptor and the cytoplasmic intracellular third loop of the D<sub>2</sub> dopamine receptor. The position of the insert of 29 amino acids in the D<sub>2</sub> long receptor is indicated by shading.



**Fig. 2.** Visualization of expression of D<sub>5</sub> and D<sub>2</sub>-NLS dopamine receptors. (A) D<sub>5</sub> (RFP) (red), expressed at the cell surface. (B) D<sub>5</sub> (RFP) (red) and D<sub>2</sub>-nls (GFP) (green) co-translocated to the nucleus. (C) C1 (D<sub>5</sub>)(RFP) (red) and D<sub>2</sub>-nls (GFP) (green) did not co-translocate to the nucleus. (D) C4 (D<sub>5</sub>)(RFP) (red) and D<sub>2</sub>-nls (GFP) (green) co-translocated to the nucleus. (E) C5 (D<sub>5</sub>)(RFP) (red) and D<sub>2</sub>-nls (GFP) (green) co-translocated to the nucleus. (F) C3 (D<sub>5</sub>)(RFP) (red) and D<sub>2</sub>-nls (GFP) (green) did not co-translocate to the nucleus. (G) C6 (D<sub>5</sub>)(RFP) (red) and D<sub>2</sub>-nls (GFP) (green) co-translocated to the nucleus. (H) D<sub>5</sub> (RFP) (red) and D<sub>2</sub>-nls (RR to AA) (GFP) (green) did not co-translocate to the nucleus. (I) D<sub>5</sub> (RFP) (red) and D<sub>1</sub>-nls (GFP) (green) co-translocated to the nucleus. (J) D<sub>5</sub> (RFP) (red) and D<sub>1</sub>-nls (GFP) (green) co-translocated to the nucleus. Each size bar in figures showing cells indicates length of 10 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

**Table 1A**  
D<sub>5</sub> dopamine receptor constructs.

		Heteromer
W/T	EVDND E E E G P F D R	Yes
C1	EVDND A A A G P F D R	No
C2	EVDND E A A G P F D R	No
C3	EVDND E A E G P F D R	No
C4	EVDND A E E G P F D R	Yes
C5	EVDND E E A G P F D R	Yes
C6	EVDN A E E G P F D R	Yes

with D<sub>1</sub>-nls to the nucleus. When D<sub>1</sub> receptor-nls was co-expressed with D<sub>5</sub> receptor construct, C1 (EEE to AAA), the D<sub>1</sub>-D<sub>5</sub> heteromers remained together indicating that these D<sub>5</sub> receptor glutamic acids residues were not involved in forming D<sub>1</sub>-D<sub>5</sub> heteromers.

4. Discussion

There are several accomplishments regarding the oligomeric structures of the D<sub>5</sub>-D<sub>2</sub> dopamine receptors reported. (i) We determined that of three adjacent glutamic acids (429-EEE) in the c-tail

of the D<sub>5</sub> receptor, any -EE pair was sufficient to form heteromers with the D<sub>2</sub> receptor. (ii) We determined adjacent arginines (274-RR) located in ic3 of the D<sub>2</sub> receptor, were involved in forming heteromers with the D<sub>5</sub> receptor. (iii) We identified single amino acid changes in the D<sub>5</sub> receptor that disrupted the D<sub>5</sub>-D<sub>2</sub> heteromers. (iv) We also determined that in the c-tail of the D<sub>5</sub> receptor glutamic acid residues (429-EEE) were not involved in D<sub>5</sub>-D<sub>1</sub> receptor heteromer formation. Thus our GPCR-nls incorporation strategy has now enabled elucidation of cytoplasmic structural features of two dopamine receptor families D<sub>5</sub>-D<sub>2</sub>, and D<sub>1</sub>-D<sub>2</sub> receptor heteromers [8].

Despite the overall lack of homology in the ~ninety amino acids residues in the c-tails of D<sub>1</sub> and D<sub>5</sub> receptors, contiguous glutamic acids were located in equivalent positions and each shown to be involved in forming heteromers. The D<sub>1</sub> and D<sub>2</sub> dopamine receptors form heteromers with D<sub>5</sub> receptor using different interacting residues. Although the residues involved in D<sub>1</sub>-D<sub>5</sub> heteromers have not yet been identified, potentially involving TM regions.

Interestingly the rat D<sub>5</sub> receptor c-tail contains five contiguous glutamic acids, presumably involved in forming heteromers with the D<sub>2</sub> receptor (Table 1B). Thus heteromer formation with these various glycine pairs, (potentially forming heteromers with any of four possible -EE pairs), interact with arginines in ic3 of the D<sub>2</sub> dopamine receptor permitting minor variations in the

**Table 1B**D<sub>5</sub> dopamine receptor cytoplasmic tail sequence in mammalian species.

Human D5	E V D N D <b>E E E</b> G P F D
Rat D5	E V G <b>E E E E E</b> G P F D
Mouse D5	E V G <b>E E E E A E E E</b> G P F D
Dog D5	E V D K Q <b>E E</b> S P F D

conformation of the D<sub>5</sub>–D<sub>2</sub> heteromer cytoplasmic structures. The mouse D<sub>5</sub> receptor has a total of four glutamic acids in a row then alanine and three additional contiguous glutamic acids, (Table 1B), allowing 6 different EE pairings in heteromer formation with the D<sub>2</sub> receptor. In comparison the D<sub>1</sub> dopamine receptor in human and rodent contains only a single glycine pair (404-EE).

Previously using the GPCR-nls strategy we identified discrete cytoplasmic regions in the mu and delta opioid receptors required for oligomer formation. In the carboxyl tail of the delta receptor we identified three glycine residues (–GGG), substitution of any of these residues prevented heteromer formation. In ic3 of both mu and delta receptors we identified three residues (–SVR), substitution of any of these residues prevented heteromer formation.

Thus data from our studies of four heteromer families, dopamine heteromers D<sub>5</sub>–D<sub>2</sub>, D<sub>1</sub>–D<sub>2</sub>, D<sub>1</sub>–D<sub>5</sub>, and mu-delta heteromers, indicate there is not a common mechanism for heteromer formation within Family A GPCRs. Receptor heteromerization arose in the cell to increase complexity, to develop and expand the utility and versatile range of functions of each individual GPCR, thus ways of interacting with other distantly related GPCRs as heteromers were opportunistically adapted. Whereas with closely related GPCRs such as D<sub>1</sub> or D<sub>5</sub>, or mu and delta opioid receptors, these receptors maintained the formations used by homooligomer pairs, in forming heteromers.

In summary, we elucidated precise aspects of the cytoplasmic structure of D<sub>5</sub>–D<sub>2</sub> receptor heteromers. By changing single amino acids in the D<sub>5</sub> receptor c-tail we succeeded in disrupting the D<sub>5</sub> receptor ability to form heteromers. We can now prepare D<sub>5</sub> and D<sub>2</sub> receptor expressing cells incapable of forming heteromers. Thus our work on the dopamine and opioid receptors is revealing the

nature of the interactions involved in heteromers in the Family A GPCRs.

## Acknowledgments

This work was partially supported by a Proof of Principle Grant from the Canadian Institutes for Health Research and National Institute on Drug Abuse Grant (DA007223). S.R.G. holds a Canada Research Chair in Molecular Neuroscience.

## References

- [1] S.R. George, B.F. O'Dowd, S.P. Lee, G-protein-coupled receptor oligomerization and its potential for drug discovery, *Nat. Rev. Drug Discovery* 1 (2002) 808–820.
- [2] G. Milligan, G-protein-coupled receptor heterodimerization: contribution to pharmacology and function, *Br. J. Pharmacol.* 158 (2009) 5–14.
- [3] F. Ciruela, A. Vallano, J.M. Arnau, S. Sánchez, D.O. Borroto-Escuela, L.F. Agnati, K. Fuxe, V. Fernández-Dueñas, G protein-coupled receptor oligomerization for what?, *J. Recept. Signal Transduction Res.* 30 (2010) 322–330.
- [4] A. Hasbi, T. Fan, M. Alijanian, T. Nguyen, M.L. Perreault, B.F. O'Dowd, S.R. George, Calcium signaling cascade links dopamine D1–D2 receptor heteromer to striatal BDNF production and neuronal growth, *Proc. Natl. Acad. Sci. USA* 106 (2009) 21377–21382.
- [5] M.L. Perreault, A. Hasbi, M. Alijanian, T. Fan, G. Varghese, P.J. Fletcher, P. Seeman, P.B.F. O'Dowd, S.R. George, The dopamine D1–D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia, *J. Biol. Chem.* 285 (2010) 36625–36634.
- [6] B.F. O'Dowd, X. Ji, M. Alijanian, T. Nguyen, S.R. George, Separation and reformation of cell surface dopamine receptor oligomers visualized in cells, *Eur. J. Pharmacol.* 658 (2011) 74–83.
- [7] B.F. O'Dowd, X. Ji, M. Alijanian, R.D. Rajaram, M.M. Kong, A. Rashid, T. Nguyen, S.R. George, Dopamine receptor oligomerization visualized in living cells, *J. Biol. Chem.* 280 (2005) 37225–37235.
- [8] B.F. O'Dowd, X. Ji, T. Nguyen, S.R. George, Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1–D2 heteromer formation, *Biochem. Biophys. Res. Commun.* 417 (2012) 23–28.
- [9] B.F. O'Dowd, X. Ji, P.B. O'Dowd, T. Nguyen, S.R. George, Disruption of the mu-delta opioid receptor heteromer, *Biochem. Biophys. Res. Commun.* 422 (2012) 556–560.
- [10] C.H. So, V. Verma, M. Alijanian, R. Cheng, A.J. Rashid, B.F. O'Dowd, S.R. George, Calcium signaling by dopamine D5 receptor and D5–D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1–D2 receptor hetero-oligomers, *Mol. Pharmacol.* 75 (2009) 843–854.
- [11] B.F. O'Dowd, M. Alijanian, X. Ji, T. Nguyen, R.M. Eglén, S.R. George, Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors, *J. Biomol. Screen.* 12 (2007) 175–185.